Dr Toni Choueiri speaks to ecancer at the 2020 ASCO GU meeting in San Francisco about the latest developments in renal cancer.
Firstly he discusses a phase I/II study of a novel oral HIF-2 α inhibitor, MK-6482 which he presented at the meeting. He states that this inhibitor was well tolerated and showed promising activity in patients with advanced clear cell renal cell carcinoma. These results have also led to the development of a phase III trial.
He also mentions the possibility of combining MK-6482 with other therapies such as VEGF tyrosine kinase inhibitors and immune checkpoint inhibitors, along with the development of a biomarker to try and understand the mechanism of response and resistance.
Dr Choureri also highlights other important studies that were presented at this year's conference.